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Abstract: Primary biliary cirrhosis (PBC) is an autoimmune cholestatic disease of the liver which affects mainly middle-
aged women characterized by progressive destruction and loss of the small intrahepatic bile ducts which in turn, may 
lead to end-stage liver disease. The typical clinical phenotype is characterized by a middle-aged female with elevated 
cholestatic enzymes and positive antimitochondrial antibodies (AMA). However, apart from this typical presentation, 
there are important variants in everyday clinical practice. These variants include the AMA-negative PBC, the isolated 
AMA positivity, the AMA-positivity in patients with well-established autoimmune hepatitis (AIH), the premature ductopenic 
PBC variant and the PBC variant with characteristics of AIH (PBC-AIH variant). In this mini-review, we summarize and 
discuss the literature data and our own experience on the PBC variants highlighting also the uncertainties and a potential 
new era of the research agenda. 
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INTRODUCTION 
Primary biliary cholangitis (PBC) also known in the 
past as primary biliary cirrhosis, is the most frequent 
autoimmune liver disease, characterized by the 
detection of antimitochondrial antibodies (AMA) or 
specific antinuclear antibodies (ANA) and progressive 
destruction and loss of the small intrahepatic bile ducts 
[1-5]. The net result is the development of significant 
cholestasis, inflammation of the portal tracts, and 
fibrosis that may lead to end stage liver disease. The 
disease predominantly affects middle-aged females 
(female/male ratio: 8-10:1 between the 5th and 6th 
decade), although the last years a considerable 
number of younger patients are diagnosed [1,2,5,6]. 
The course of the disease is unpredictable although a 
prompt and timely diagnosis at early stages seems of 
utmost importance as treatment, even at the 
asymptomatic stage, can slow progression, delay liver 
decompensation, and improve survival [6-10].  
PBC diagnosis is established by the presence of at 
least two of the following [1-4]: detection of AMA 
(positive in almost 95% of patients) or ANA PBC-
specific antibodies (anti-sp100 or anti-gp210 antibodies 
in approximately 30% of patients) [11-13], unexplained 
biochemical cholestasis (raised alkaline phosphatase 
or γ-glutamyl transpeptidase) and compatible liver 
biopsy showing non-suppurative granulomatous  
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lymphocytic cholangitis affecting interlobular and septal 
bile ducts. 
Although the vast majority of the PBC patients have 
a typical presentation (a female patient with combined 
raised cholestatic enzymes and seropositivity for AMA), 
there are important variants in everyday clinical 
practice. These variants include the AMA-negative 
PBC, the isolated AMA positivity, the AMA-positivity in 
patients with well-established autoimmune hepatitis 
(AIH), the premature ductopenic PBC variant and the 
PBC with characteristics of AIH (PBC-AIH variant; 
Table 1) [1,2,14-16]. In this mini-review, we summarize 
and discuss the literature data and our own experience 
on the PBC variants highlighting also the uncertainties 
and a potential new era of the research agenda. 
AMA-NEGATIVE PBC 
Depending on the kind of the initial laboratory 
screening, approximately 5% of PBC patients even 
though they have increased cholestatic enzymes are 
negative for AMA detection by indirect 
immunofluorescent assay using fresh frozen sections 
of rat kidney, stomach and liver tissues [3,4,14-17]. In 
these cases, the application of molecularly based 
assays, like ELISAs and immunoblot using the known 
antigenic targets of AMA can minimize the problem 
[3,4,18-20]. In addition, investigation for the PBC-
specific ANA such as anti-sp100 and anti-gp210 
antibodies is very helpful as they can establish PBC 
diagnosis when AMA is not detectable [3,4,11-13]. The 
accuracy of these antibodies for PBC diagnosis is 
equal to AMA detection and therefore, in these patients 
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there is no need of liver biopsy to confirm the 
diagnosis. 
Table 1: Variant Syndromes of Primary Biliary 
Cholangitis (PBC) 
AMA-negative PBC 
Approximately 5% of PBC patients; Liver biopsy is necessary for 
diagnosis 
PBC-specific ANA may help; Clinical manifestations, natural 
history and response to treatment are similar to AMA-positive 
PBC patients 
Isolated AMA positivity 
0.5-0.64% of healthy subjects have AMA; No treatment is 
required; 5-year development of PBC: 16%; Periodic monitoring of 
ALP is advised (yearly?) 
AMA-positivity in AIH patients 
AMA prevalence in AIH patients: 5-35%; Most studies showed no 
correlation to cholestatic histological changes in follow-up biopsies 
or response to treatment 
Large multicenter study from the IAIHG is ongoing on this issue  
Premature ductopenic variant of PBC 
Exceptional rare but severe PBC variant; Liver transplantation is 
required  
PBC – AIH variant 
Many terms have been used so far; Absence of internationally 
accepted consensus for its definition 
The Paris criteria are currently in use but are very strict and differ 
from the respective criteria for PBC and AIH diagnosis 
Liver biopsy showing interface hepatitis is mandatory for the 
diagnosis 
No randomized trials for its management; However, combined 
treatment with immunosuppressants and UDCA seems rational 
AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ALP, alkaline 
phosphatase; AIH, autoimmune hepatitis; IAIHG, international autoimmune 
hepatitis group; UDCA, ursodeoxycholic acid. 
 
However, in true autoantibodies negative cases 
(AMA and PBC-specific ANA-negative patients) a liver 
biopsy is necessary to establish a firm diagnosis [1,2]. 
The clinical manifestations, natural course and 
prognosis as well as the response to ursodeoxycholic 
acid (UDCA) therapy of AMA-negative PBC patients 
seem similar to the AMA-positive PBC patients 
[1,2,5,21,22] although there is conflicting data 
regarding the progression and severity of the disease 
for those who have reactivity against the PBC-specific 
ANA [3,4,11-13,23-26]. 
ISOLATED AMA POSITIVITY 
The detection of AMA in otherwise healthy subjects 
is not as rare as 0.5-0.64% of them may have isolated 
AMA in the absence of clinically obvious liver disease 
or elevated cholestatic enzymes [27-29]. Previous 
studies have shown histological evidence of PBC in 
about 40% of AMA-positive asymptomatic subjects with 
normal liver biochemistry, while long-term follow-up 
showed that PBC would develop in most of them 
[30,31]. However, in the same long-term study of 18 
years of follow-up, none of the patients developed 
cirrhosis, needed liver transplantation or died because 
of the presence of PBC [31]. In addition, a recent 
prospective study in AMA-positive individuals with non-
established PBC diagnosis found that only 1 out of 6 
subjects (16.7%) with AMA and normal alkaline 
phosphatase would develop PBC after 5 years of 
follow-up although the mortality rate of these subjects 
was unexpectedly higher compared to a control 
population matched for age and sex [32]. 
Taking together, all respective authorities agree that 
there is no need for treatment initiation in cases of 
isolated AMA seropositivity although a periodic 
screening every 6-12 months for the potential 
development of biochemical abnormality seems 
rational. If such abnormality is seen during follow-up 
then treatment should be the same as for classical 
PBC [1,2].  
AMA-POSITIVITY IN PATIENTS WITH WELL-
ESTABLISHED AIH 
Although AMA isthe serological hallmark for PBC 
diagnosis, they occasionally detected in patients with 
other liver disorders, including AIH but their clinical 
significance under these circumstances is obscure. In a 
recent systematic review of our group, the detection of 
AMA in patients with AIH was not uncommon, with a 
prevalence ranging from 5% to as high as 35% in some 
Japanese studies, depending mainly on the method 
employed [2]. However, most of the studies so far have 
shown that this finding represents simply a bystander 
phenomenon without any clinical significance, although 
there are serious limitations such as a short follow-up, 
infrequent sequential histological examination and 
inclusion of a small number of patients. 
In this context, Montano-Loza et al. reported an 
AMA prevalence of 18% in AIH patients (24/130; 
follow-up: 123 months), but their presence was not 
associated with clinical or histological features of PBC 
at presentation, cholestatic histological changes at 
sequential liver biopsies, while remission and treatment 
failures were similar between AMA-positive and AMA-
negative patients with AIH [33]. Similar findings have 
been reported by our group [34] and O’ Brien et al. [35]. 
In the latter study, a very long-term follow-up of 27 
years has been reported in 15 AIH patients with 
detectable AMA (15/126; 12%) but again no bile duct 
damage characteristic of PBC was seen on initial or 
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follow-up liver biopsies, while the clinical course 
remained typical of AIH and there was no difference on 
treatment response compared to AMA-negative 
patients with AIH [35]. 
However, Dinani et al. [36] reported three 
persistently AMA-positive patients with AIH who 
developed PBC over time. Of note, one of these three 
patients had been previously reported in the above-
mentioned cohort by O’ Brien et al. [35], indicating 
perhaps that much longer follow-up is needed to detect 
late development of PBC in AMA-positive AIH patients. 
Finally, in a very recent multicentre study on 47 AMA-
positive AIH cases, it was shown in the univariate 
analysis that AMA reactivity was significantly 
associated with older age and a better response to 
immunosuppression compared with 264 AMA-negative 
AIH patients [37]. However, after multivariate logistic 
regression analysis using AMA as a dependent 
variable, there was no statistically significant difference 
while none of the AMA-positive patients with AIH 
showed signs of PBC manifestations after a median 
follow-up of 4 years [37]. In summary, these patients 
should be treated as for AMA-negative patients with 
AIH according to the common clinical practice 
guidelines for the management of AIH [14-17].  
We should emphasize herein, however, that the 
International AIH Group (IAIHG) is currently running a 
large multicentre retrospective study based on 
prospectively collected data on AMA issue in patients 
with AIH in order to definitely address first, the 
prevalence of AMA in AIH patients at presentation and 
long-term follow-up, second, the significance of AMA 
seropositivity in AIH in terms of demographic, clinical, 
serological, biochemical and histological characteristics 
of the patients at baseline and during follow-up and 
third, the long-term outcome and treatment response of 
AMA-positive patients with AIH compared to age and 
sex-matched AMA-negative AIH patients. 
PREMATURE DUCTOPENIC VARIANT OF PBC 
A rare premature ductopenic PBC variant has been 
reported, in which severe pruritus is associated with 
progressive cholestasis with jaundice [38,39].Of note, 
this variant is not responsive to UDCA treatment. Liver 
biopsy shows extensive bile duct loss but without 
significant fibrosis or cirrhosis while, the affected 
patients usually are rapidly in need for liver 
transplantation either because of persistent and 
intractable itching or progressive jaundice [1,2]. 
Therefore, the referral of these patients to expert 
centers is highly recommended. As pregnancy may 
add cholestasis during the last trimester and post-
partum, this fact could also be deleterious for those 
women with an already established ductopenic PBC 
variant.  
PBC – AIH VARIANT 
a. Definition and Diagnosis 
A small proportion of around 8-10% of PBC patients 
exhibits also clinical characteristics of AIH [1,2,14-17]. 
This happens either simultaneously or consecutively 
(patients with established PBC who develop features of 
AIH) while some patients with AIH may also present 
PBC characteristics (patients with established AIH who 
develop features of PBC). Many terms have been used 
in the past to describe this syndrome like “hepatitic 
form of PBC”, “PBC with secondary AIH” and “PBC-AIH 
overlap syndromes”. However, the previous term 
“overlap” used for years to describe these disorders 
strongly suggests the simultaneous presence of two 
distinct diseases, which is not the case for all patients 
and therefore, this term could be a misnomer 
[15,16,40-42]. Recently, the term “variant” has been 
proposed by the European Association for the Study of 
the Liver (EASL), which is thought to be more precise 
for these conditions [15]. 
In the absence of internationally accepted 
consensus criteria for the precise definition of PBC - 
AIH variant its diagnosis is usually difficult. The “Paris 
criteria” are still the most frequently used in everyday 
clinical practice (Table 2) [43]. However, these criteria 
are robust and from our experience less than 50% of 
patients with AIH fulfil these criteria (in particular for the 
cut-off of serum levels of IgG). In this context, a recent 
study from China showed that the PBC – AIH variant 
may be identified very efficiently using the Paris 
criteria, but after lowering the IgG threshold to 1.3 
times the upper limit of normal instead of 2.0 times, 
further supporting the concerns for underestimation of 
diagnosis of this condition by using the original criteria 
published in 1998 [44]. Moreover, it should be kept in 
mind that the Paris criteria are different from the 
respective definitions for PBC and AIH [1,2,15,16]. 
Notably, both the revised (Table 3) [45] and the 
simplified score (Table 4) [46] for the diagnosis of AIH 
have not been developed to diagnose these variant 
forms of PBC and therefore, they should not be used in 
routine clinical practice for the diagnosis of PBC-AIH 
variants [1,2,14-17,40,47,48]. Testing of autoantibodies 
against soluble liver antigen/liver pancreas (anti-
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SLA/LP) by immunobloting or ELISA should be 
considered in the laboratory workup of patients with 
PBC and suspected AIH as these autoantibodies have 
been reported in patients with PBC-AIH variant [49-51]. 
Table 2: Paris Criteria for the Diagnosis of PBC – AIH 
Variant Syndrome (Adapted from ref. [43]) 
PBC 
ALP > 2 xULN or γ-GT > 5 xULN 
AMA detection (cut-off titer: ≥ 1:40) 
Liver biopsy showing florid bile duct lesions 
AIH  
ALT > 5xULN 
Serum IgG> 2 x ULN or SMA detection 
Liver biopsy showing moderate or severe periportal or periseptal 
lymphocytic piecemeal necrosis (interface hepatitis) 
PBC-AIH variant syndrome requires the presence of at least 2 out of 3 key 
criteria for each disease. PBC, primary biliary cirrhosis; AIH, autoimmune 
hepatitis; ALP, alkaline phosphatase; ULN, upper limit of normal; γ-GT, 
gamma-glutamyltranspeptidase; AMA, antimitochondrial antibodies; ALT, 
alanine aminotransferase; IgG, immunoglobulin G; SMA, smooth muscle 
antibodies. 
 
Table 3: Revised Scoring System for Autoimmune 
Hepatitis Diagnosis (Adapted from [45]) 
Parameter/Features Score 
Gender: Female/Male +2/0 
Degree of elevation above ULN of alkaline 
phosphatase vs. aminotransferases 
 
- <1.5 +2 
- 1.5 – 3.0 0 
- >3.0 -2 
Total serum globulins, γ-globulins, or IgG above normal 
- >2.0 +3 
- 1.5 – 2.0 +2 
- 1.0 – 1.5 +1 
- <1.0 0 
ANA, SMA or LKM-1 titers by immunofluorescence 
- >1 : 80 +3 
- 1 : 80 +2 
- 1 : 40 +1 
- <1 : 40 0 
- AMA positive -4 
(Table 3). Continued. 
Parameter/Features Score 
Hepatitis markers (IgM anti-HAV, HBsAg, IgM anti-HBc, anti-
HCV, HCV RNA) 
- Positive/Negative -3/+3 
Recent or current use of known or suspected hepatotoxic 
drugs 
- Yes/No -4/+1 
Average alcohol intake 
- <25 g/day / >60 g/day +2/-2 
Other autoimmune disease(s) in patient or first degree 
relatives 
- Yes/No +2/0 
Additional parameters (only if ANA, SMA or LKM-1 are 
negative) 
- HLA DR3, DR4, or other HLA with published 
association with AIH 
+1 
- Positivity for any of ANCA, anti-LC1, anti-SLA/LP, 
anti-ASGPR and anti-sulfatide 
+2 
Liver histology 
- Interface hepatitis +3 
- Predominant lymphoplasmacytic infiltrate +1 
- Rosetting of liver cells +1 
- None of the above -5 
- Biliary changes -3 
- Other changes -3 
Response to therapy: Complete/Relapse +2/+3 
Definite AIH if greater than 15 before treatment or greater than 17 post-
treatment; probable AIH if between 10-15 before treatment or 12-17 post-
treatment; IgG, immunoglobulin G; ANA, antinuclear antibodies; SMA, smooth 
muscle antibodies; anti-LKM1, anti-liver/kidney microsomal antibody type-1; 
AMA, antimitochondrial antibodies; HLA, human leukocyte antigens; AIH, 
autoimmune hepatitis; ANCA, anti-neutrophil cytoplasmic antibodies; anti-LC1, 
antibodies against liver cytosol type-1 antigen; anti-SLA/LP, antibodies against 
soluble liver antigens/liver pancreas; anti-ASGPR, antibodies against the 
asialoglycoprotein receptor; IgM anti-HAV, hepatitis A virus IgM antibody; 
HBsAg, surface antigen of hepatitis B virus; IgM anti-HBc, IgM antibody against 
the core antigen of hepatitis B virus; ULN, upper limit of normal. 
 
Unlike several uncertainties, the recent clinical 
practice guidelines on PBC diagnosis and management 
of EASL and the British Society of Gastroenterology 
(BSG) [1,2] recommend liver histology as a mandatory 
tool for the assessment of patients with this variant 
form of PBC. Particularly, liver biopsy with expert 
histopathology review seems crucial because of 
potential therapeutic implications in the PBC cases that 
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do not respond to UDCA having also disproportional 
elevations of alanine aminotransferase (ALT) and/or 
IgG [1,2]. 
In summary, it should be kept in mind that PBC-AIH 
variants should not be over-diagnosed in order not to 
make vulnerable PBC patients to the risk of side effects 
of immunosuppressive therapy but on the other hand, 
physicians should also be aware that it is unclear 
whether the use of strict cut-offs of the Paris criteria is 
efficient to identify all PBC patients who would 
potentially benefit from immunosuppression. For this 
reason, patients with autoimmune liver diseases are 
better to be categorized initially as AIH, PBC, or 
primary sclerosing cholangitis, taking into account the 
predominant manifestations and those with additional 
features should not be considered as being distinct 
diagnostic and clinical entities [14-17,40,41]. 
b. Natural History and Management 
Problems on the precise definition of PBC-AIH 
variant along with their low prevalence have resulted in 
the inability of carrying out controlled trials concerning 
their management. Most retrospective studies, 
however, albeit the small number of patients suffering 
from a PBC-AIH variant, have shown a more severe 
course compared to patients with PBC alone as 
attested by the earlier development of portal 
hypertension, decompensated cirrhosis and the need 
of liver transplantation or death [52-59]. Taking into 
account the above findings, treatment with a 
combination of UDCA and immunosuppressive therapy 
in order to treat both disease elements seems 
reasonable as, besides inherent problems in definition 
and diagnosis, recent meta-analyses have shown that 
combination therapy was more effective than UDCA 
alone [58,60]. 
In line with the abovementioned findings, the recent 
EASL and BSG clinical practice guidelines for PBC 
management have recommended adding 
immunosuppression (steroids alone or in combination 
with azathioprine) to UDCA in previously diagnosed 
PBC cases if at least moderate interface hepatitis is 
present at the histological level [1,2]. However, the 
recent EASL clinical practice guidelines for AIH 
diagnosis and management recommend treatment for 
AIH patients even at lower cut-offs of ALT or IgG and a 
histological activity index as low as 4 indicating further 
the difficulties in managing patients with these variant 
syndromes [15]. In particular, in patients with dominant 
AIH characteristics, an alternative approach is to start 
with immunosuppression only and then add UDCA if 
the response is insufficient [15,16]. 
Of note, it has been reported that PBC-AIH patients 
appear to respond to fewer immunosuppression 
dosages and maintain remission after treatment 
withdrawal at higher rates than patients with AIH only 
[53,58]. In non-responders after the initial 
immunosuppressive therapy, alternative agents like 
Table 4: Simplified Criteria for Autoimmune Hepatitis Diagnosis (Adapted from [46]) 
Parameter/Feature Finding Points 
ANA or SMA pos ≥ 1:40 +1 
ANA or SMA pos 
or anti-LKM pos 





Liver histology (presence 
of hepatitis is necessary) 
Typical AIH** 





Serum IgG levels > Upper normal limit 
> 1.1 x Upper normal limit 
+1 
+2 




Sum  ≥ 6: probable AIH 
 ≥ 7: definite AIH 
*Addition of points achieved for all autoantibodies (maximum, 2 points). **Definition of typical lesions: presence of interface hepatitis, hepatocyte rosetting and 
emperipolesis; Compatible liver histology: chronic hepatitis with lymphocytic infiltration without all the features considered typical; Atypical: histological lesions 
supporting another diagnosis. ***In chronic cases absence of hepatitis B and C viral markers; in acute cases absence of serological markers of acute hepatitis A, B, 
C, D and E is needed. ANA, antinuclear antibodies; SMA, smooth muscle antibodies; anti-LKM, anti-liver/kidney microsomal antibody; anti-SLA/LP, antibodies 
against soluble liver antigens/liver pancreas; AIH, autoimmune hepatitis; IgG, immunoglobulin G. 
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mycophenolate mofetil, cyclosporin or tacrolimus can 
be used [14,16,17,58,61,62]. It is not certain if AIH 
patients who develop manifestations of PBC will benefit 
from UDCA addition but it seems logical under real-life 
conditions, particularly in young patients, because of 
the potential long-term benefit of UDCA administration, 
which may subsequently protect the patients from the 
development of ductopenia and biliary cirrhosis during 
their lifetime. 
CONCLUDING REMARKS AND RESEARCH 
AGENDA 
Apart from the typical presentation of a female 
patient with combined raised cholestatic enzymes and 
seropositivity for AMA, there are important variants in 
everyday clinical practice including the AMA-negative 
PBC, the isolated AMA positivity, the AMA-positivity in 
patients with AIH, the premature ductopenic PBC 
variant and the PBC-AIH variant. Because of their 
relative rarity, these variant forms of PBC and in 
particular, the PBC-AIH variant suffer from several 
inherent difficulties in definition, diagnosis, investigation 
of pathogenesis and management. The following 
uncertainties in PBC-AIH variant may help scientists to 
design well organized, concentrated and pioneer 
multicenter research collaborations that can guide to 
better understanding of its pathogenesis and treatment 
options. 
• Do we need new criteria apart from the Paris 
criteria with “lower cut-offs” of IgG and 
aminotransferases in order to proceed to liver 
biopsy in a PBC patient with suspicion of PBC-
AIH variant presence? 
• Which patient with PBC will benefit from 
immunosuppression? (grade of 
necroinflammatory activity – other markers e.g. 
anti-SLA/LP antibodies) 
• Validation of the old criteria and the unmet need 
for a specific diagnostic scoring system for the 
diagnosis of PBC-AIH variants 
• Which is the degree of histological bile duct 
lesion that defines PBC in patients with an 
already established AIH diagnosis? 
• Do these patients require additional UDCA 
treatment? 
• Do we need randomized controlled trials for the 
management of PBC-AIH variants?  
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